You are here

Nerve Ablation Device Gets 501(k) Clearance for Chronic Pain

Minimally Invasive Procedure Uses Radio Waves to Thwart Pain

Medtronic has received FDA clearance for its Accurian radio-frequency ablation system for nerve tissues; the device is designed to treat chronic pain via a minimally invasive procedure.

A current produced by radio waves heats up small patches of nerves to stop them from sending pain signals. The system also uses advanced software that controls the amount of power delivered and the temperature of the procedure, ensuring more consistent and predictable lesion formations.

Medtronic says that its Accurian platform can perform standard, pulsed, and enhanced ablation procedures, using internally cooled radio frequency probes to create various lesion shapes, sizes, and volumes. It has independent channel control and chip-enhanced probes for easy on-screen identification, and smart features, such as downloadable procedure reports.

Chronic pain is a disabling condition that affects approximately 100 million American adults. The annual treatment cost of chronic pain and related lost productivity is estimated to be $635 billion.

Source: FierceBiotech, February 27, 2019; Medtronic, February 27, 2019

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM